Results 261 to 270 of about 1,156,192 (336)

Validation of target‐enriched enzymatic methylation sequencing for brain tumor classification from formalin‐fixed paraffin embedded‐derived DNA

Brain Pathology, EarlyView.
Target‐enriched enzymatic methylation sequencing (TEEM‐seq), a DNA methylation sequencing method using the Twist Human Methylome panel, shows comparable performance to array‐based tumor methylation profiling. The method is compatible with both frozen and formalin‐fixed paraffin‐embedded (FFPE) samples and is a viable approach to tumor methylation and ...
Quynh T. Tran, Sujuan Jia, Md. Zahangir Alom, Lu Wang, Charles G. Mullighan, Ruth G. Tatevossian, Brent A. Orr   +6 more
wiley   +1 more source

Washington University Medical Alumni Quarterly, July 1944 [PDF]

, 1944

core   +1 more source

Miliary Tuberculosis Causing Presumed Primary Adrenal Insufficiency and Addisonian Crisis: A Case Report from Rural Kenya

Vonwicks C. Onyango, Boniface Mutiso, Nicholas Muriithi Mutuma, Collins Paul Malalu, Nicholas Auma, William C. Fryda   +5 more
openalex   +2 more sources

Adrenal Crisis

Nihon Naika Gakkai Zasshi, 2012
openaire   +4 more sources

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Assessment of the molecular mechanisms of drug‐induced hidden cardiotoxicity by a multi‐omics approach: The example of rofecoxib

British Journal of Pharmacology, EarlyView.
Background and Purpose Hidden cardiotoxicity is defined as drug‐induced cardiotoxicity that becomes obvious only in the presence of comorbidities. However, the molecular mechanisms of hidden cardiotoxicity are not always known. Therefore, unbiased multi‐omics approaches could assist in revealing regulatory pathways.
Bennet Y. Weber, Gábor B. Brenner, Barnabás Váradi, Bence Ágg, Csenger Kovácsházi, Olivér M. Balogh, Donagh Egan, Kieran Wynne, David Matallanas, Rainer Schulz, Péter Ferdinandy, Zoltán Giricz, Anikó Görbe   +12 more
wiley   +1 more source

Synthetic microneurotrophins: Neurotrophin receptors for therapeutics of neurodegenerative diseases

British Journal of Pharmacology, EarlyView.
Neurodegenerative disorders are characterised by the chronic progressive degeneration of specific neuronal subtypes, neuroinflammation, myelin damage and synaptic loss. Despite their growing incidence, advancements in effective treatments remain limited, because of lack of knowledge for the aetiology of the diverse pathophysiology to design systematic ...
Ioanna Zota, Theodora Calogeropoulou, Konstantina Chanoumidou, Ioannis Charalampopoulos, Achille Gravanis   +4 more
wiley   +1 more source

Non‐canonical PKG1 regulation in cardiovascular health and disease

British Journal of Pharmacology, EarlyView.
It is well established that the cyclic GMP‐dependent protein kinase I (PKG1) is canonically activated by cyclic guanosine monophosphate (cGMP), enabling its regulation of vascular tone, cardiac function and smooth muscle homeostasis. However, diverse non‐canonical stimuli of PKG1 have also been identified.
Jie Su, Joseph Robert Burgoyne
wiley   +1 more source